Omega promo web banner
Omega promo Mobile banner

Abbott, MSD Pharmaceuticals enter into partnership

19 Jun 2025 Evaluate

Abbott and MSD Pharmaceuticals have entered into partnership for distribution of oral anti-diabetic medicines in India. Under a distribution agreement, Abbott will distribute the oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version of MSD Pharmaceuticals (MSD) in India. MSD's sitagliptin, its combination and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Abbott will leverage its broad in-country footprint to continue to make these medicines available to people in India. 

Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor (DPP4i) used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008.

Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India. 

Abbott India Share Price

34409.95 -201.15 (-0.58%)
11-Jul-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.50
Dr. Reddys Lab 1254.00
Cipla 1485.05
Lupin 1892.70
Zydus Lifesciences 979.60
View more..
Register Now to get our Free Newsletter & much more!
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...